Related Experiment Video

Updated: Jun 3, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Oral anti-diabetic drugs for the prevention of Type 2 diabetes

O J Phung1, N A Sood, B E Sill

  • 1Western University of Health Sciences College of Pharmacy, Pomona, CA, USA.

Diabetic Medicine : a Journal of the British Diabetic Association
|March 25, 2011
PubMed
Abstract

Insights

Thiazolidinediones were most effective in preventing Type 2 diabetes, significantly reducing risk compared to control and other oral anti-diabetic drugs. Alpha-glucosidase inhibitors and biguanides also showed benefits, while sulphonylureas and glinides did not.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Preventive Medicine

Background:

  • Type 2 diabetes is a growing global health concern.
  • Identifying effective interventions to prevent diabetes is crucial.
  • Oral anti-diabetic drugs are commonly used, but their comparative efficacy in prevention is not fully established.

Purpose of the Study:

  • To compare the efficacy of various oral anti-diabetic drugs in preventing the development of Type 2 diabetes.
  • To identify which drug classes offer the greatest risk reduction.

Main Methods:

  • Systematic literature search of major databases (MEDLINE, EMBASE, Cochrane CENTRAL).
  • Inclusion of randomized controlled trials in high-risk individuals.
  • Application of mixed-treatment comparison meta-analysis to assess relative risks and risk differences.

Main Results:

  • Twenty trials with 23,230 participants were analyzed.
  • Thiazolidinediones demonstrated the greatest risk reduction (64%) compared to control.
  • Alpha-glucosidase inhibitors (40%) and biguanides (27%) also showed significant risk reduction.
  • Sulphonylureas and glinides had no significant preventive effect.

Conclusions:

  • Thiazolidinediones are the most effective oral anti-diabetic drug class for preventing Type 2 diabetes.
  • Alpha-glucosidase inhibitors and biguanides offer significant preventive benefits.
  • Sulphonylureas and glinides are not effective for diabetes prevention.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...